COVID-19 candidate vaccine
Potential treatment - pre-clinical evidence
LNP-nCoVsaRNA is a COVID-19 candidate vaccine being developed by Imperial College London. It is an saRNA type of candidate vaccine. It is based on the RNA platform, which is also used for non-COVID-19 candidates, such as EBOV, LASV, MARV, Inf (H7N9), and RABV. Currently, this COVID-19 candidate vaccine is in Phase I clinical trial.
|Link||Tested on||Impact factor||Notes||Publication date||DB entry date|
|DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020||in vitro||Mar/26/2020||Apr/03/2020|